Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365715 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1CA12CA9 | |
| SCHEMBL3343193 | 0.99 | ALDH1A1 (0.39) | CA1CA2ALDH1A1CA12CA9 | |
| SCHEMBL6853749 | 0.92 | ALDH1A1 (0.38) | CA1CA2ALDH1A1CA12CA9 | |
| SCHEMBL6852562 | 0.92 | ALDH1A1 (0.38) | CA1CA2ALDH1A1CA12CA9 | |
| SCHEMBL6849012 | 0.89 | PSMD10 (0.37) | CA1CA2ALDH1A1CA12CA9 | |
| SCHEMBL6849019 | 0.89 | PSMD10 (0.37) | CA1CA2ALDH1A1CA12CA9 | |
| SCHEMBL9995667 | 0.88 | CA12 (0.40) | CA1CA2ALDH1A1CA12CA9 | |
| SCHEMBL5531391 | 0.88 | PSMD10 (0.38) | CA1CA2ALDH1A1CA12CA9 | |
| SCHEMBL6534983 | 0.86 | CA1 (0.34) | CA1CA2ALDH1A1CA12CA9 | |
| SCHEMBL4335889 | 0.85 | CA2 (0.39) | CA1CA2ALDH1A1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491244-B2 | Labeled fluorocarbon agents for positron emission tomography imaging | Sunnybrook Research Institute (CA) | 2022-11-08 | — | — | US | disclosed |
| US-7226578-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SHERING AG (DE) | 2007-06-05 | — | — | US | disclosed |
| US-6916461-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20030232012-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6468502-B1 | PARAMAGNETIC MACROMOLECULES WITH HIGHER PROTON RELAXIVITY; LOWER DOSAGE AND INCREASED SIGNAL INTENSITY; DETECTING VASCULAR DISEASES; DIFFERENTIATING TISSUE BLOOD SUPPLY LEVELS; DISTINGUISHING MYOCARDIAL INFARCTION FROM ISCHEMIA | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-22 | — | — | US | disclosed |
| EP-0874645-B1 | PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THEIR USE IN NMR DIAGNOSTICS | SCHERING AG (DE) | 2002-04-03 | — | — | EP | disclosed |
| EP-0882010-B1 | PHARMACEUTICAL AGENTS CONTAINING PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THE USE THEREOF IN TUMOUR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-05-02 | — | — | EP | disclosed |
| US-6180113-B1 | USED IN TUMOR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-01-30 | — | — | US | disclosed |
| EP-0874645-A2 | PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THEIR USE IN NMR DIAGNOSTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997026017-A2 | PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THEIR USE IN NMR DIAGNOSTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | FABP1, FLOT1, AFF1 | CA1 2320/4885CA2 1733/4885ALDH1A1 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.